In another signal of the appetite among investors for companies applying artificial intelligence to drug discovery, Pathos AI has gathered an impressive $365 million in fourth-round financing as it ...
London-listed PRTech firm Pathos Communications has built a proprietary AI platform, PathosMind, for internal use by its employees and partners. The system is designed to identify stories that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback